The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Fungal Infections Rarer, Linked With Worse Prognosis in Patients Receiving CAR T-Cell Therapy

July 25th 2022, 10:25pm


Overall, infections occurred in 18.42% of cases and typically occurred within the first month, significantly dropping from then on.

Dosing Study of Modakafusp Alfa Shows Promise in Solid Tumors; Tests Planned With Checkpoint Inhibitors

July 22nd 2022, 1:09pm


Lucitanib With Nivolumab Sees Responses in Gynecological Cancer Treatment

July 22nd 2022, 12:59pm


Data Indicate Lower Response Rates to Axi-cel Among Black Patients

July 22nd 2022, 12:36pm


ASCO Spotlight With Kim A. Reiss, MD, on CAR Macrophages and Other Developments in Pancreatic Cancer

July 21st 2022, 6:44pm


Kim A. Reiss, MD, assistant program director, assistant professor of medicine, Hospital of the University of Pennsylvania, Philadelphia, discusses 2 abstracts presented during ASCO.

Inspection Delays Prompt FDA Deferral on Tislelizumab in Second-line ESCC

July 14th 2022, 5:33pm


Patients With Cancer Face Major Financial Roadblocks, Not All Concerning Out-of-Pocket Costs

July 7th 2022, 8:01pm


Abstracts presented at this year's American Society of Clinical Oncology Annual meeting detailed the financial hardships many patients with cancer face, including those related to high-deductible health plans and clinical trial participation.

Dr Zahra Mahmoudjafari Explains How Payers Can Better Manage CAR T Costs, Increase Access

July 2nd 2022, 6:17pm


Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, explains some of the strategies that payers can use to improve cost management and increase patient access related to chimeric antigen receptor T-cell (CAR T) therapies.

Dr Zahra Mahmoudjafari Previews CAR T Therapies Coming Down the Pipeline

June 23rd 2022, 8:17pm


Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”

June 23rd 2022, 7:41pm


Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.